Design, Evaluation and Comparative Study of Pulsatile Releasefrom Tablet and Capsule Dosage Forms Pulsatile release from tablet and capsule dosage forms
Iranian Journal of Pharmaceutical Sciences,
Vol. 5 No. 3 (2009),
1 July 2009
,
Page 119-128
https://doi.org/10.22037/ijps.v5.41206
Abstract
The objective of present research was to design, evaluate and compare drug release from two different dosage forms in pulsatile drug delivery system (DDS) for Metoprolol tartarate (MT) as tablet and capsule. Pulsatile systems are gaining a lot of interest as they deliver the drug at the right site of action at the right time and inthe right amount, thus providing spatial and temporal delivery and in creasingpatient compliance. These systems are designed according to the circadian rhythm of the body. The principle rationale for the use of pulsatile release is for the drugs where a constant drug release, i.e., a zero-order release is not desired. The release of the drug as a pulse after a lag time has to be designed in such a way that a complete and rapid drug release follows the lag time. Conclusively, the current study attained the successful comparison of drug release from two different pulsatile drug delivery systems.
- Drug delivery system
- Release study
- Metoprolol
- Pulsatile
How to Cite
References
[2]Qiu Y, Zhang G. Research and development aspects of oral controlled-release dosage forms,In: Wise DL, (editor). Handbook of pharmaceutical controlled release technology.New York: Marcel Dekker, 2000; pp. 465-504.
[3]Shweta JA, Alka A, Sanjula B, Qureshi J, Arora S. Pulsatile drug delivery systems: An approach for controlled drug delivery. Indian J Pharm Sci2006; 68: 295-300.
[4]Bussemer T, Otto I, Bodmeier R. Pulsatile drug-delivery systems. Crit Rev Ther Drug Carrier Syst2001; 18: 433-58.
[5]Bussemer T, Bodmeier R. Review of pulsatile drug delivery. Am Pharm Rev2001; 4: 18-24.
[6]Ritschel WA, Forusz H. Chronopharmacology: Areview of drugs studies. Meth Find Exp Clin Pharmacol1994; 16: 57-75.
[7]Lemmer B. Chronopharmacokinetics:Implications for drug treatment. J Pharm Pharmacol1999; 51: 887-90.
[8]Survase S, Kumar N. Pulsatile drug delivery:Current scenario. CRIPS2007; 8: 27-33.
[9]Banker GS, Rhodes CT. Modern Pharmaceutics.2nded. Vol. 40. New York: Marcel Dekker, 1990;p. 449.
[10]www. evonik.com
[11]Scheiffele S, Ascherl H, Ruchatz F, Kolter K.Gastric resistance of kollicoat MAE 100 P-Aredispersible powder of methacrylic acid copolymer type c. http://www.aapspharmsci.org/abstracts/AM_1999/1661.htm
[12]United states pharmacopoeia XXIVNF 19.Roukville: United States Pharmacopoeial Convention, 2006; pp. 2673-80.
[13]Lachman L, Lieberman HA, Kanig JL. The theory and practice of industrial pharmacy. Mumbai:Varghese Publishing House, 1991; p. 361.
- Abstract Viewed: 295 times
- IJPS_Volume 5_Issue 3_Pages 119-128 Downloaded: 204 times